Psoriasis Patients in Phase 1 Trial Receiving KY1005-CT01, a Potential Bowel Disease Therapy

Psoriasis Patients in Phase 1 Trial Receiving KY1005-CT01, a Potential Bowel Disease Therapy
A 24th psoriasis patient has received KY1005-CT01 in a Phase 1 clinical trial of the treatment designed to fight the autoimmune disorder affecting the skin and other organs. KY1005 has the potential to treat several autoimmune disorders, including inflammatory bowel disease, or IBD. An autoimmune disease is one in which the immune system, whose job is

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *